Vanguard Group
COCP icon

Vanguard Group’s Cocrystal Pharma COCP Stock Holding History

Vanguard Group’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$258K Sell
263,987
-4,093
-2% -$4.33K ﹤0.01% 4068
2025
Q3 		$335K Hold
268,080
– – ﹤0.01% 4038
2025
Q2 		$399K Sell
268,080
-7,576
-3% -$11.3K ﹤0.01% 3973
2025
Q1 		$391K Hold
275,656
– – ﹤0.01% 3933
2024
Q4 		$557K Hold
275,656
– – ﹤0.01% 3920
2024
Q3 		$485K Hold
275,656
– – ﹤0.01% 3977
2024
Q2 		$642K Hold
275,656
– – ﹤0.01% 3923
2024
Q1 		$386K Hold
275,656
– – ﹤0.01% 4071
2023
Q4 		$475K Hold
275,656
– – ﹤0.01% 4040
2023
Q3 		$515K Buy
275,656
+4,211
+2% +$10.6K ﹤0.01% 4044
2023
Q2 		$649K Hold
271,445
– – ﹤0.01% 4037
2023
Q1 		$540K Hold
271,445
– – ﹤0.01% 4108
2022
Q4 		$529K Buy
271,445
+188
+0.1% +$482 ﹤0.01% 4082
2022
Q3 		$948K Hold
271,257
– – ﹤0.01% 4019
2022
Q2 		$1.33M Sell
271,257
-1,463
-0.5% -$7.79K ﹤0.01% 3988
2022
Q1 		$1.8M Sell
272,720
-880
-0.3% -$5.85K ﹤0.01% 3997
2021
Q4 		$2.13M Sell
273,600
-317
-0.1% -$3.25K ﹤0.01% 4010
2021
Q3 		$3.45M Buy
273,917
+15,331
+6% +$203K ﹤0.01% 3857
2021
Q2 		$3.88M Buy
258,586
+95,438
+58% +$1.45M ﹤0.01% 3721
2021
Q1 		$2.72M Hold
163,148
– – ﹤0.01% 3792
2020
Q4 		$2.66M Buy
163,148
+58,477
+56% +$812K ﹤0.01% 3583
2020
Q3 		$1.17M Buy
104,671
+34,733
+50% +$634K ﹤0.01% 3624
2020
Q2 		$1.28M Sell
69,938
-1,749
-2% -$21.4K ﹤0.01% 3549
2020
Q1 		$611K Buy
71,687
+41,707
+139% +$393K ﹤0.01% 3627
2019
Q4 		$179K Hold
29,980
– – ﹤0.01% 3957
2019
Q3 		$734K Sell
29,980
-50
-0.2% -$1.3K ﹤0.01% 3724
2019
Q2 		$847K Buy
30,030
+1,278
+4% +$38K ﹤0.01% 3721
2019
Q1 		$942K Buy
28,752
+4,823
+20% +$176K ﹤0.01% 3637
2018
Q4 		$1.03M Buy
23,929
+11,398
+91% +$376K ﹤0.01% 3555
2018
Q3 		$376K Buy
12,531
+10,814
+630% +$484K ﹤0.01% 3898
2018
Q2 		$75K Buy
+1,717
New +$63.7K ﹤0.01% 4076

Other funds holding COCP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Vanguard Group's COCP Position: Q4 2025 in Review

Vanguard Group reduced its Cocrystal Pharma (COCP) stake by 1.5% in Q4 2025, selling an estimated $4.33K and leaving 263,987 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

Vanguard Group first reported a position in COCP in Q2 2018 and has held it in 31 quarters since. The position peaked at $3.88M in Q2 2021. 28 funds tracked by Wall St. Rank hold COCP as of Q4 2025.

  • Vanguard Group held 263,987 shares of Cocrystal Pharma worth $258K as of Q4 2025.
  • Vanguard Group sold 4,093 Cocrystal Pharma shares in Q4 2025, an estimated $4.33K.
  • Cocrystal Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4068 holding.
  • Vanguard Group first reported a position in Cocrystal Pharma in Q2 2018 and has held it in 31 quarters since.
  • Vanguard Group's Cocrystal Pharma position peaked at $3.88M in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.